comparemela.com

Latest Breaking News On - Specialized drugs - Page 5 : comparemela.com

Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy

By Zaeem Shoaib Shares of Greenwich LifeSciences rose after the company said it is preparing for filing a biologics license application for its experimental.

United statesZaeem shoaibDrug administrationGreenwich lifesciencesArticle normalBiotechnology servicesCancer drugsHealthcare life sciencesBiological therapySpecialized drugs medicationsHealthcare provisionFinancial performanceShare price movement disruptionsCorporate industrial newsBreast cancerPolitical general news

Kairos Pharma to sell 1 55 million shares in IPO at $4 each

Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.

Kairos pharmaBen glickmanLos angeles basedArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsCorporate changesStock listingsCorporate fundingShare capitalInitial public offeringsOwnership changesAcquisitions mergers shareholdingsCorporate actionsCorporate industrial news

BioXcel Therapeutics Shares Rise 13% After Public Offering Terminated

By Chris Wack BioXcel Therapeutics shares were up 13% at $2.21 after the company terminated its proposed public offering of $60 million of shares or.

Chris wackDrug administration on febXcel therapeuticsDrug administrationArticle normalHealthcare life sciencesSpecialized drugs medicationsFinancial performanceShare price movement disruptionsCorporate industrial newsEquity marketsCommodity financial market newsContent typesFactiva filtersC amp ampe exclusion filterC amp ampe industry news filter

Shares G1 Therapeutics Tumble 46% Following Update to Phase 3 Breast Cancer Study

By Josh Beckerman Shares of G1 Therapeutics fell 46% to $2.44 in after-hours trading on Monday after the company provided an update to its Phase 3.

Josh beckermanDrug administrationData monitoring committeeArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingBreast cancerPolitical general newsDemographic healthMedical conditions

Zoetis 4Q Net Up 14%, Sees 2024 Growth on Strong Pet, Livestock Demand

By Rob Curran Zoetis's fourth-quarter net income rose 14% as the animal-health company benefited from a continued boom in pet care and a robust U.S. farming.

New zealandRob curranWall streetArticle normalHealthcare life sciencesSpecialized drugs medicationsFinancial performanceCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterIndustrial newsLife sciencesSpecialized drugs

vimarsana © 2020. All Rights Reserved.